;PMID: 9327727
;source_file_1307.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..34] = [t:0..34]
;1)sentence:[e:39..153] = [t:39..153]
;2)sentence:[e:154..214] = [t:154..214]
;3)section:[e:218..323] = [t:218..323]
;4)section:[e:327..414] = [t:327..414]
;5)sentence:[e:418..591] = [t:418..591]
;6)sentence:[e:592..810] = [t:592..810]
;7)sentence:[e:811..927] = [t:811..927]
;8)sentence:[e:928..1082] = [t:928..1082]
;9)sentence:[e:1083..1161] = [t:1083..1161]
;10)sentence:[e:1162..1394] = [t:1162..1394]
;11)sentence:[e:1395..1450] = [t:1395..1450]
;12)sentence:[e:1451..1596] = [t:1451..1596]
;13)sentence:[e:1598..1648] = [t:1598..1648]
;14)sentence:[e:1649..1853] = [t:1649..1853]
;15)section:[e:1857..1901] = [t:1857..1901]

;section 0 Span:0..34
;Am J Pathol  1997 Oct;151(4):943-9
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..11] Pathol) (CD:[13..17] 1997)
        (CD:[18..25] Oct;151) (-LRB-:[25..26] -LRB-) (CD:[26..27] 4)
        (-RRB-:[27..28] -RRB-) (CD:[28..33] :943-) (CD:[33..34] 9)))

;sentence 1 Span:39..153
;Can K-ras codon 12 mutations be used to distinguish benign bile duct 
;proliferations from metastases in the liver?
;[43..48]:gene-rna:"K-ras"
;[49..57]:variation-location:"codon 12"
;[58..67]:variation-event:"mutations"
;[129..139]:malignancy-clinical-stage:"metastases"
(SENT
  (SQ-HLN (MD:[39..42] Can)
    (NP-SBJ-1 (NN:[43..48] K-ras)
      (NML (NN:[49..54] codon) (CD:[55..57] 12))
      (NNS:[58..67] mutations))
    (VP (VB:[68..70] be)
      (VP (VBN:[71..75] used)
        (NP-1 (-NONE-:[75..75] *))
        (S-ADV
          (NP-SBJ (-NONE-:[75..75] *))
          (VP (TO:[76..78] to)
            (VP (VB:[79..90] distinguish)
              (NP (JJ:[91..97] benign)
                (NML (NN:[98..102] bile) (NN:[103..107] duct))
                (NNS:[109..123] proliferations))
              (PP (IN:[124..128] from)
                (NP
                  (NP (NNS:[129..139] metastases))
                  (PP-LOC (IN:[140..142] in)
                    (NP (DT:[143..146] the) (NN:[147..152] liver))))))))))
    (.:[152..153] ?)))

;sentence 2 Span:154..214
;A molecular analysis of 101 liver  lesions from 93 patients.
;[182..196]:malignancy-type:"liver  lesions"
(SENT
  (NP
    (NP (DT:[154..155] A) (JJ:[156..165] molecular) (NN:[166..174] analysis))
    (PP (IN:[175..177] of)
      (NP
        (NP (CD:[178..181] 101)
           (NN:[182..187] liver) (NNS:[189..196] lesions))
        (PP (IN:[197..201] from)
          (NP (CD:[202..204] 93) (NNS:[205..213] patients)))))
    (.:[213..214] .)))

;section 3 Span:218..323
;Hruban RH, Sturm PD, Slebos RJ, Wilentz RE, Musler AR, Yeo CJ, Sohn TA, van 
;Velthuysen ML, Offerhaus GJ.
(SEC
  (FRAG (NNP:[218..224] Hruban) (NNP:[225..227] RH) (,:[227..228] ,)
        (NNP:[229..234] Sturm) (NNP:[235..237] PD) (,:[237..238] ,)
        (NNP:[239..245] Slebos) (NNP:[246..248] RJ) (,:[248..249] ,)
        (NNP:[250..257] Wilentz) (NNP:[258..260] RE) (,:[260..261] ,)
        (NNP:[262..268] Musler) (NNP:[269..271] AR) (,:[271..272] ,)
        (NNP:[273..276] Yeo) (NNP:[277..279] CJ) (,:[279..280] ,)
        (NNP:[281..285] Sohn) (NNP:[286..288] TA) (,:[288..289] ,)
        (NNP:[290..293] van) (NNP:[295..305] Velthuysen) (NNP:[306..308] ML)
        (,:[308..309] ,) (NNP:[310..319] Offerhaus) (NNP:[320..323] GJ.)))

;section 4 Span:327..414
;Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, 
;Maryland, USA.
(SEC
  (FRAG (NNP:[327..337] Department) (IN:[338..340] of)
        (NNP:[341..350] Pathology) (NNP:[350..351] ,) (NNP:[352..357] Johns)
        (NNP:[358..365] Hopkins) (NNP:[366..373] Medical)
        (NNP:[374..386] Institutions) (,:[386..387] ,)
        (NNP:[388..397] Baltimore) (,:[397..398] ,) (NNP:[400..408] Maryland)
        (,:[408..409] ,) (NNP:[410..413] USA) (.:[413..414] .)))

;sentence 5 Span:418..591
;It can be difficult to distinguish benign bile duct proliferations (BDPs)
;from  well-differentiated metastatic peripancreatic adenocarcinomas on
;histological  grounds alone.
;[518..528]:malignancy-clinical-stage:"metastatic"
;[529..559]:malignancy-type:"peripancreatic adenocarcinomas"
(SENT
  (S
    (NP-SBJ (PRP:[418..420] It))
    (VP (MD:[421..424] can)
      (VP (VB:[425..427] be)
        (ADJP-PRD (JJ:[428..437] difficult)
          (S
            (NP-SBJ (-NONE-:[437..437] *))
            (VP (TO:[438..440] to)
              (VP (VB:[441..452] distinguish)
                (NP (JJ:[453..459] benign)
                  (NML
                    (NML
                      (NML (NN:[460..464] bile) (NN:[465..469] duct))
                      (NNS:[470..484] proliferations))
                    (NML (-LRB-:[485..486] -LRB-)
                      (NP (NNS:[486..490] BDPs))
                      (-RRB-:[490..491] -RRB-))))
                (PP (IN:[492..496] from)
                  (NP
                    (ADJP (RB:[498..502] well) (HYPH:[502..503] -)
                          (VBN:[503..517] differentiated))
                    (JJ:[518..528] metastatic)
                     (JJ:[529..543] peripancreatic)
                     (NNS:[544..559] adenocarcinomas)))
                (PP (IN:[560..562] on)
                  (NP (JJ:[563..575] histological) (NNS:[577..584] grounds)
                    (ADVP (RB:[585..590] alone))))))))))
    (.:[590..591] .)))

;sentence 6 Span:592..810
;Most peripancreatic carcinomas harbor activating point mutations  in codon 12
;of the K-ras oncogene, suggesting that K-ras mutational status may  provide a
;molecular basis for distinguishing BDPs from liver metastases.
;[597..622]:malignancy-type:"peripancreatic carcinomas"
;[641..656]:variation-type:"point mutations"
;[661..669]:variation-location:"codon 12"
;[677..682]:gene-rna:"K-ras"
;[709..714]:gene-rna:"K-ras"
;[793..798]:malignancy-type:"liver"
;[799..809]:malignancy-clinical-stage:"metastases"
(SENT
  (S
    (NP-SBJ (JJS:[592..596] Most)
       (JJ:[597..611] peripancreatic) (NNS:[612..622] carcinomas))
    (VP (VBP:[623..629] harbor)
      (NP (VBG:[630..640] activating)
         (NN:[641..646] point) (NNS:[647..656] mutations))
      (PP-LOC (IN:[658..660] in)
        (NP
          (NP (NN:[661..666] codon) (CD:[667..669] 12))
          (PP (IN:[670..672] of)
            (NP (DT:[673..676] the) (NN:[677..682] K-ras)
                (NN:[683..691] oncogene)))))
      (,:[691..692] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[692..692] *))
        (VP (VBG:[693..703] suggesting)
          (SBAR (IN:[704..708] that)
            (S
              (NP-SBJ (NN:[709..714] K-ras) (JJ:[715..725] mutational)
                      (NN:[726..732] status))
              (VP (MD:[733..736] may)
                (VP (VB:[738..745] provide)
                  (NP
                    (NP (DT:[746..747] a) (JJ:[748..757] molecular)
                        (NN:[758..763] basis))
                    (PP (IN:[764..767] for)
                      (S-NOM
                        (NP-SBJ (-NONE-:[767..767] *))
                        (VP (VBG:[768..782] distinguishing)
                          (NP (NNS:[783..787] BDPs))
                          (PP (IN:[788..792] from)
                            (NP (NN:[793..798] liver)
                                (NNS:[799..809] metastases))))))))))))))
    (.:[809..810] .)))

;sentence 7 Span:811..927
;The  ability of tests for mutations in codon 12 of K-ras to make this
;distinction was  examined in a two-part study.
;[837..846]:variation-event:"mutations"
;[850..858]:variation-location:"codon 12"
;[862..867]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[811..814] The) (NN:[816..823] ability)
        (S-1 (-NONE-:[823..823] *ICH*)))
      (PP (IN:[824..826] of)
        (NP
          (NP (NNS:[827..832] tests))
          (PP (IN:[833..836] for)
            (NP
              (NP (NNS:[837..846] mutations))
              (PP-LOC (IN:[847..849] in)
                (NP
                  (NP (NN:[850..855] codon) (CD:[856..858] 12))
                  (PP (IN:[859..861] of)
                    (NP (NN:[862..867] K-ras)))))))))
      (S-1
        (NP-SBJ (-NONE-:[867..867] *))
        (VP (TO:[868..870] to)
          (VP (VB:[871..875] make)
            (NP (DT:[876..880] this) (NN:[881..892] distinction))))))
    (VP (VBD:[893..896] was)
      (VP (VBN:[898..906] examined)
        (NP-2 (-NONE-:[906..906] *))
        (PP (IN:[907..909] in)
          (NP (DT:[910..911] a)
            (NML (CD:[912..915] two) (HYPH:[915..916] -) (NN:[916..920] part))
            (NN:[921..926] study)))))
    (.:[926..927] .)))

;sentence 8 Span:928..1082
;In the first part we determined the K-ras  mutational status of 56 liver
;lesions and 48 primary peripancreatic  adenocarcinomas obtained from 48
;patients.
;[964..969]:gene-rna:"K-ras"
;[995..1008]:malignancy-type:"liver lesions"
;[1016..1023]:malignancy-clinical-stage:"primary"
;[1024..1055]:malignancy-type:"peripancreatic  adenocarcinomas"
(SENT
  (S
    (PP (IN:[928..930] In)
      (NP (DT:[931..934] the) (JJ:[935..940] first) (NN:[941..945] part)))
    (NP-SBJ (PRP:[946..948] we))
    (VP (VBD:[949..959] determined)
      (NP
        (NP (DT:[960..963] the)
          (NML (NN:[964..969] K-ras))
          (JJ:[971..981] mutational) (NN:[982..988] status))
        (PP (IN:[989..991] of)
          (NP
            (NP
              (NP (CD:[992..994] 56)
                 (NN:[995..1000] liver) (NNS:[1001..1008] lesions))
              (CC:[1009..1012] and)
              (NP (CD:[1013..1015] 48) (JJ:[1016..1023] primary)
                 (JJ:[1024..1038] peripancreatic)
                 (NNS:[1040..1055] adenocarcinomas)))
            (VP (VBN:[1056..1064] obtained)
              (NP (-NONE-:[1064..1064] *))
              (PP (IN:[1065..1069] from)
                (NP (CD:[1070..1072] 48) (NNS:[1073..1081] patients))))))))
    (.:[1081..1082] .)))

;sentence 9 Span:1083..1161
;In the second part of this study an  additional 45 liver lesions were
;studied.
;[1134..1147]:malignancy-type:"liver lesions"
(SENT
  (S
    (PP (IN:[1083..1085] In)
      (NP
        (NP (DT:[1086..1089] the) (JJ:[1090..1096] second)
            (NN:[1097..1101] part))
        (PP (IN:[1102..1104] of)
          (NP (DT:[1105..1109] this) (NN:[1110..1115] study)))))
    (NP-SBJ-1 (DT:[1116..1118] an) (JJ:[1120..1130] additional)
              (CD:[1131..1133] 45)
       (NN:[1134..1139] liver) (NNS:[1140..1147] lesions))
    (VP (VBD:[1148..1152] were)
      (VP (VBN:[1153..1160] studied)
        (NP-1 (-NONE-:[1160..1160] *))))
    (.:[1160..1161] .)))

;sentence 10 Span:1162..1394
;In the first 48 patients, activating  point mutations in codon 12 of K-ras
;were detected in 28 (61%) of the 46 primary  carcinomas, in 8 (100%) of 8
;liver metastases, in 2 (6.5%) of 31 BDPs, and in  none (0%) of 14 liver
;granulomas.
;[1200..1215]:variation-type:"point mutations"
;[1219..1227]:variation-location:"codon 12"
;[1231..1236]:gene-rna:"K-ras"
;[1273..1280]:malignancy-clinical-stage:"primary"
;[1282..1292]:malignancy-type:"carcinomas"
;[1311..1316]:malignancy-type:"liver"
;[1317..1327]:malignancy-clinical-stage:"metastases"
;[1377..1393]:malignancy-type:"liver granulomas"
(SENT
  (S
    (PP (IN:[1162..1164] In)
      (NP (DT:[1165..1168] the) (JJ:[1169..1174] first) (CD:[1175..1177] 48)
          (NNS:[1178..1186] patients)))
    (,:[1186..1187] ,)
    (NP-SBJ-1
      (NP (VBG:[1188..1198] activating)
         (NN:[1200..1205] point) (NNS:[1206..1215] mutations))
      (PP-LOC (IN:[1216..1218] in)
        (NP
          (NP (NN:[1219..1224] codon) (CD:[1225..1227] 12))
          (PP (IN:[1228..1230] of)
            (NP (NN:[1231..1236] K-ras))))))
    (VP (VBD:[1237..1241] were)
      (VP (VBN:[1242..1250] detected)
        (NP-1 (-NONE-:[1250..1250] *))
        (PP-LOC
          (PP (IN:[1251..1253] in)
            (NP
              (NP (CD:[1254..1256] 28)
                (PRN (-LRB-:[1257..1258] -LRB-)
                  (NP (CD:[1258..1260] 61) (NN:[1260..1261] %))
                  (-RRB-:[1261..1262] -RRB-)))
              (PP (IN:[1263..1265] of)
                (NP (DT:[1266..1269] the) (CD:[1270..1272] 46)
                    (JJ:[1273..1280] primary) (NNS:[1282..1292] carcinomas)))))
          (,:[1292..1293] ,)
          (PP (IN:[1294..1296] in)
            (NP
              (NP (CD:[1297..1298] 8)
                (PRN (-LRB-:[1299..1300] -LRB-)
                  (NP (CD:[1300..1303] 100) (NN:[1303..1304] %)
                      (-RRB-:[1304..1305] -RRB-))))
              (PP (IN:[1306..1308] of)
                (NP (CD:[1309..1310] 8) (NN:[1311..1316] liver)
                    (NNS:[1317..1327] metastases)))))
          (,:[1327..1328] ,)
          (PP (IN:[1329..1331] in)
            (NP
              (NP (CD:[1332..1333] 2)
                (PRN (-LRB-:[1334..1335] -LRB-)
                  (NP (CD:[1335..1338] 6.5) (NN:[1338..1339] %))
                  (-RRB-:[1339..1340] -RRB-)))
              (PP (IN:[1341..1343] of)
                (NP (CD:[1344..1346] 31) (NNS:[1347..1351] BDPs)))))
          (,:[1351..1352] ,) (CC:[1353..1356] and)
          (PP (IN:[1357..1359] in)
            (NP
              (NP (NN:[1361..1365] none)
                (PRN (-LRB-:[1366..1367] -LRB-)
                  (NP (CD:[1367..1368] 0) (NN:[1368..1369] %))
                  (-RRB-:[1369..1370] -RRB-)))
              (PP (IN:[1371..1373] of)
                (NP (CD:[1374..1376] 14)
                   (NN:[1377..1382] liver) (NNS:[1383..1393] granulomas))))))))
    (.:[1393..1394] .)))

;sentence 11 Span:1395..1450
;Three BDPs and two primary carcinomas did not  amplify.
;[1414..1421]:malignancy-clinical-stage:"primary"
;[1422..1432]:malignancy-type:"carcinomas"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1395..1400] Three) (NNS:[1401..1405] BDPs))
      (CC:[1406..1409] and)
      (NP (CD:[1410..1413] two) (JJ:[1414..1421] primary)
          (NNS:[1422..1432] carcinomas)))
    (VP (VBD:[1433..1436] did) (RB:[1437..1440] not)
      (VP (VB:[1442..1449] amplify)))
    (.:[1449..1450] .)))

;sentence 12 Span:1451..1596
;To further estimate the prevalence of K-ras mutations in BDPs we  analyzed an
;additional series of 45 mostly incidental BDPs for K-ras mutations.
;[1489..1494]:gene-rna:"K-ras"
;[1580..1585]:gene-rna:"K-ras"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[1451..1451] *))
      (VP (TO:[1451..1453] To)
        (ADVP (RB:[1454..1461] further))
        (VP (VB:[1462..1470] estimate)
          (NP
            (NP (DT:[1471..1474] the) (NN:[1475..1485] prevalence))
            (PP (IN:[1486..1488] of)
              (NP
                (NP (NN:[1489..1494] K-ras) (NNS:[1495..1504] mutations))
                (PP-LOC (IN:[1505..1507] in)
                  (NP (NNS:[1508..1512] BDPs)))))))))
    (NP-SBJ (PRP:[1513..1515] we))
    (VP (VBD:[1517..1525] analyzed)
      (NP
        (NP (DT:[1526..1528] an) (JJ:[1529..1539] additional)
            (NN:[1540..1546] series))
        (PP (IN:[1547..1549] of)
          (NP
            (NP (CD:[1550..1552] 45)
              (ADJP (RB:[1553..1559] mostly) (JJ:[1560..1570] incidental))
              (NNS:[1571..1575] BDPs))
            (PP (IN:[1576..1579] for)
              (NP (NN:[1580..1585] K-ras) (NNS:[1586..1595] mutations)))))))
    (.:[1595..1596] .)))

;sentence 13 Span:1598..1648
;Three (6.7%) of these 45 harbored K-ras mutations.
;[1632..1637]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1598..1603] Three)
        (PRN (-LRB-:[1604..1605] -LRB-)
          (NP (CD:[1605..1608] 6.7) (NN:[1608..1609] %))
          (-RRB-:[1609..1610] -RRB-)))
      (PP (IN:[1611..1613] of)
        (NP (DT:[1614..1619] these) (CD:[1620..1622] 45))))
    (VP (VBD:[1623..1631] harbored)
      (NP (NN:[1632..1637] K-ras) (NNS:[1638..1647] mutations)))
    (.:[1647..1648] .)))

;sentence 14 Span:1649..1853
;These results suggest that  K-ras mutations may be useful in distinguishing
;BDPs from metastases in the  liver; however, there is some overlap in the
;mutational spectra of BDPs and  pancreatic carcinomas.
;[1677..1682]:gene-rna:"K-ras"
;[1735..1745]:malignancy-clinical-stage:"metastases"
;[1831..1852]:malignancy-type:"pancreatic carcinomas"
(SENT
  (S
    (NP-SBJ (DT:[1649..1654] These) (NNS:[1655..1662] results))
    (VP (VBP:[1663..1670] suggest)
      (SBAR (IN:[1671..1675] that)
        (S
          (NP-SBJ (NN:[1677..1682] K-ras) (NNS:[1683..1692] mutations))
          (VP (MD:[1693..1696] may)
            (VP (VB:[1697..1699] be)
              (ADJP-PRD (JJ:[1700..1706] useful))
              (PP (IN:[1707..1709] in)
                (S-NOM
                  (NP-SBJ (-NONE-:[1709..1709] *))
                  (VP (VBG:[1710..1724] distinguishing)
                    (NP (NNS:[1725..1729] BDPs))
                    (PP (IN:[1730..1734] from)
                      (NP
                        (NP (NNS:[1735..1745] metastases))
                        (PP (IN:[1746..1748] in)
                          (NP (DT:[1749..1752] the) (NN:[1754..1759] liver))))))))))))
      (::[1759..1760] ;)
      (S-ADV
        (ADVP (RB:[1761..1768] however))
        (,:[1768..1769] ,)
        (NP-SBJ (EX:[1770..1775] there))
        (VP (VBZ:[1776..1778] is)
          (NP-PRD (DT:[1779..1783] some) (NN:[1784..1791] overlap))
          (PP (IN:[1792..1794] in)
            (NP
              (NP (DT:[1795..1798] the) (JJ:[1799..1809] mutational)
                  (NNS:[1810..1817] spectra))
              (PP (IN:[1818..1820] of)
                (NP
                  (NP (NNS:[1821..1825] BDPs))
                  (CC:[1826..1829] and)
                  (NP (JJ:[1831..1841] pancreatic) (NNS:[1842..1852] carcinomas)))))))))
    (.:[1852..1853] .)))

;section 15 Span:1857..1901
;PMID: 9327727 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1857..1861] PMID) (::[1861..1862] :) (CD:[1863..1870] 9327727)
        (NN:[1871..1872] -LSB-) (NNP:[1872..1878] PubMed) (::[1879..1880] -)
        (NN:[1881..1888] indexed) (IN:[1889..1892] for)
        (NNP:[1893..1901] MEDLINE-RSB-)))
